ABSTRACT SUBMISSION



KEY DATES FOR 

ABSTRACT SUBMISSION

Call for Abstracts: Now Open

Call for Abstracts Close: 23 September 2025

Abstract Author Notification: Expected early December 2025

Author Registration Deadline: Mid January 2026

Meeting Dates: 2 - 4 March 2026



Abstract submissions are invited for the following:

  • Oral Presentation – please note that there are a limited number of positions available for Oral Presentations. These will be selected by the Scientific Committee.
  • Poster Presentation – these will be displayed for the duration of the meeting with an allocated time for the presenting author to be available for questions. Posters are to be AO poster size.

Program Themes:

  • Acute Lymphoblastic Leukaemia
  • Acute Myeloid Leukaemia
  • Cell Therapy
  • Chronic Lymphocytic Leukaemia
  • Epigenetics
  • Genomics
  • Immunotherapy
  • Lymphoma
  • Metabolism
  • Myelodysplasic syndrome
  • Myeloma
  • Myeloproliferative neoplasms including Chronic Myeloid Leukaemia
  • Paediatric Leukaemia
  • Stem Cells and Microenvironment
  • New Therapeutic Approaches 

Abstract Submission Instructions:

Please read through the submission instructions listed below before preparing your abstract:

Step 1: Write your abstract following the Abstract Guidelines and using the Abstract Template
Step 2: Click on the below SUBMIT YOUR ABSTRACT button to complete the Abstract Submission and follow the prompts.

Submit Your Abstract

Who submits the abstract?
The Presenting Author must submit the abstract and will act as the main point of contact for the abstract with organisers.

Once you enter the online submission portal, start by creating an account. Upon successful submission of the abstract a confirmation email will be sent to the Presenting Author.

If you have not received a confirmation email, please check that your abstract is not left in draft and is fully submitted by logging back into the portal and checking on the Edit/View Abstracts page.

How to Edit a Submitted Abstract?
You can save your submission as a draft and return to edit the submission at a later point. It is important to note that once it has been submitted the abstract cannot be edited after the abstract submission deadline. Ensure that your abstract is not left in draft as it will not be reviewed.

Authors will be notified of their abstract submission status: expected early December 2025.

Presentation Format:

The Scientific Committee reserves the right to decide the format of presentation on the basis of time and space available.

Please note:

All presenters must be registered for the Conference, and are responsible for their own registration fees, personal travel and accommodation expenses.

The Event Managers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events.


JOIN THE MAILING LIST

Join the mailing list to be kept up to date with information on the New Directions in Leukaemia Research 2026 Meeting. Join mailing list here.

SOCIAL MEDIA

Join the conversation with #NDLR20266

EVENT MANAGER

Event Studio Group 

For all conference enquiries, please talk to the team at Event Studio Group Pty Ltd:

E: NDLR2026@eventstudio.com.au  |  P: +61 (08) 8379 8222

To view the privacy statement, click here